iCardiac Technologies Completes Industry’s Largest Validation Study of Highly Automated QT Analysis

ROCHESTER, N.Y.--(BUSINESS WIRE)--iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarkers, today announced the successful completion of the industry’s largest validation study for an automated ECG analysis technology. The results of the study make iCardiac’s highly automated technology the first to comply with the FDA E14 industry guidance.

Back to news